InSphero acquired PhenoVista Biosciences, a cell-based assay services provider, to expand its high-content imaging and phenotypic assay capabilities for drug development. The deal adds services spanning oncology, fibrosis, and safety assessment and is intended to support InSphero’s growth into neuroscience and neurotoxicity testing. The acquisition also strengthens InSphero’s US footprint, complementing earlier organoid and assay expansion moves. Financial terms were not disclosed. For biopharma developers, the integration may broaden access to phenotypic assay platforms used for compound triage and translational readouts, especially where target-based screening has limitations.